PLS3 and colorectal carcinoma: To further validate the suitability of either marker tested for discrimination of particularly malignant and benign colorectal diseases, the expression levels of CK20, PLS3, LAD1, and DEFA5 for healthy controls, IID and CRC patients were subjected to ROC curve analysis for estimation of the discriminatory power between the variables.